|
|
| Zeile 3: |
Zeile 3: |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| − | {{tp|p=32371564|t=2020. Clinical presentation and course of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32366502|t=2020. COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies |pdf=|usr=}}
| |
| − | {{tp|p=32252141|t=2020. Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19) |pdf=|usr=}}
| |
| − | {{tp|p=32252139|t=2020. Epidemiology and clinical features of coronavirus disease 2019 in children |pdf=|usr=}}
| |
| − | {{tp|p=32207680|t=2020. COVID-19: the new challenge for rheumatologists |pdf=|usr=}}
| |
| − | {{tp|p=32197957|t=ä. What Should Gastroenterologists and Patients Know About COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32276137|t=ä. Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32325252|t=2020. COVID-19 pathophysiology: A review |pdf=|usr=}}
| |
| − | {{tp|p=32139372|t=2020. What we know so far: COVID-19 current clinical knowledge and research |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 40: |
Zeile 31: |
| | | | |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| − | {{tp|p=32145275|t=2020. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis |pdf=|usr=}}
| |
| − | {{tp|p=32348783|t=2020. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis |pdf=|usr=}}
| |
| − | {{tp|p=32202240|t=2020. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?|pdf=|usr=}}
| |
| − | {{tp|p=32301997|t=ä. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 76: |
Zeile 63: |
| | *'''[[Dermatology]]''' | | *'''[[Dermatology]]''' |
| | *'''[[Gastroenterology, hepatology]]''' | | *'''[[Gastroenterology, hepatology]]''' |
| − | {{tp|p=32371556|t=2020. Hyperglycemia management in the critically ill patient with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32205220|t=ä. Don t Overlook Digestive Symptoms in Patients With 2019 Novel Coronavirus Disease (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32278065|t=ä. Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention and management |pdf=|usr=}}
| |
| − | {{tp|p=32334083|t=ä. Current Knowledge and Research Priorities in the Digestive Manifestations of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32311512|t=ä. Diarrhea is associated with prolonged symptoms and viral carriage in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32283325|t=ä. Clinical Features of COVID-19-Related Liver Damage |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 87: |
Zeile 68: |
| | * | | * |
| | *'''[[Pathobiology]]''' | | *'''[[Pathobiology]]''' |
| − | {{tp|p=32334082|t=ä. ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection |pdf=|usr=}}
| |
| − | {{tp|p=32270184|t=ä. Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32307550|t=ä. Down-regulated gene expression spectrum and immune responses changed during the disease progression in COVID-19 patients |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32234451|t=ä. COVID-19, SARS and MERS: are they closely related?|pdf=|usr=}}
| |
| | | | |
| | *'''[[Disease Models]]''' | | *'''[[Disease Models]]''' |
| Zeile 99: |
Zeile 75: |
| | * | | * |
| | *'''[[Diagnosis (Laboratory)]]''' | | *'''[[Diagnosis (Laboratory)]]''' |
| − | {{tp|p=32360478|t=2020. Emerging key laboratory tests for patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32077933|t=ä. ...Why Partnership between Clinical Laboratories, Public Health Agencies, and Industry Is Essential to Control the Outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32154877|t=ä. The SARS-CoV-2 Outbreak: Diagnosis, Infection Prevention, and Public Perception |pdf=|usr=}}
| |
| − | {{tp|p=32246822|t=ä. Potential false-negative nucleic acid testing results for Severe Acute Respiratory Syndrome Coronavirus 2 from thermal inactivation of samples with low viral loads |pdf=|usr=}}
| |
| − | {{tp|p=32353116|t=ä. Modeling SARS-CoV-2 positivity using laboratory data: timing is everything |pdf=|usr=}}
| |
| − | {{tp|p=32343775|t=ä. SARS-CoV-2 Serology: Much Hype, Little Data |pdf=|usr=}}
| |
| − | {{tp|p=32315390|t=ä. Rapid detection of COVID-19 coronavirus using a reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic platform |pdf=|usr=}}
| |
| − | {{tp|p=32282874|t=ä. Limits of Detection of Six Approved RT?PCR Kits for the Novel SARS-coronavirus-2 (SARS-CoV-2) |pdf=|usr=}}
| |
| − | {{tp|p=32031590|t=ä. Racing Towards the Development of Diagnostics for a Novel Coronavirus (2019-nCoV) |pdf=|usr=}}
| |
| − | {{tp|p=32229107|t=2020. Dynamic change process of target genes by RT-PCR testing of SARS-Cov-2 during the course of a Coronavirus Disease 2019 patient |pdf=|usr=}}
| |
| − | {{tp|p=32031583|t=ä. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32156607|t=ä. Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32343948|t=2020. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study |pdf=|usr=}}
| |
| − | {{tp|p=32335089|t=ä. Highly sensitive detection of SARS-CoV-2 RNA by multiplex rRT-PCR for molecular diagnosis of COVID-19 by clinical laboratories |pdf=|usr=}}
| |
| − | {{tp|p=32315614|t=2020. Laboratory data analysis of novel coronavirus (COVID-19) screening in 2510 patients |pdf=|usr=}}
| |
| − | {{tp|p=32295319|t=2020. Innovative screening tests for COVID-19 in South Korea |pdf=|usr=}}
| |
| − | {{tp|p=32358960|t=ä. Evaluation of COVID-19 RT-qPCR test in multi-sample pools |pdf=|usr=}}
| |
| − | {{tp|p=32357209|t=ä. Early detection of SARS-CoV-2 antibodies in COVID-19 patients as a serologic marker of infection |pdf=|usr=}}
| |
| − | {{tp|p=32357206|t=ä. Role of serology in the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32221523|t=ä. Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients |pdf=|usr=}}
| |
| − | {{tp|p=32221519|t=ä. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32047895|t=ä. Consistent Detection of 2019 Novel Coronavirus in Saliva |pdf=|usr=}}
| |
| − | {{tp|p=32271374|t=ä. Effect of throat washings on detection of 2019 novel coronavirus |pdf=|usr=}}
| |
| − | {{tp|p=32337590|t=ä. Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |pdf=|usr=}}
| |
| − | {{tp|p=32241023|t=ä. Gargle lavage as a safe and sensitive alternative to swab samples to diagnose COVID-19: a case report in Japan |pdf=|usr=}}
| |
| − | {{tp|p=32306047|t=ä. Antibody Detection and Dynamic Characteristics in Patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32306042|t=ä. Testing for SARS-CoV-2: Can We Stop at Two?|pdf=|usr=}}
| |
| − | {{tp|p=32276116|t=ä. Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay |pdf=|usr=}}
| |
| − | {{tp|p=32306036|t=ä. Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients |pdf=|usr=}}
| |
| | | | |
| | *'''[[Diagnosis (Lung CT, Sonography)]]''' | | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| − | {{tp|p=32120312|t=2020. Asymptomatic novel coronavirus pneumonia patient outside Wuhan: The value of CT images in the course of the disease |pdf=|usr=}}
| |
| − | {{tp|p=32302927|t=2020. Portable chest X-ray in coronavirus disease-19 (COVID-19): A pictorial review |pdf=|usr=}}
| |
| − | {{tp|p=32361535|t=ä. COVID-19 pneumonia patient without clear epidemiological history outside Wuhan: An analysis of the radiographic and clinical features |pdf=|usr=}}
| |
| − | {{tp|p=32361413|t=2020. Initial CT imaging characters of an imported family cluster of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32358955|t=ä. Still much to learn about the diagnostic role of SARS-CoV-2 antibody detection |pdf=|usr=}}
| |
| − | {{tp|p=32232429|t=ä. Computed Tomographic Imaging of 3 Patients With Coronavirus Disease 2019 Pneumonia With Negative Virus Real-time Reverse-Transcription Polymerase Chain Reaction Test |pdf=|usr=}}
| |
| − | {{tp|p=32227091|t=ä. Novel Coronavirus Pneumonia (COVID-19) Progression Course in 17 Discharged Patients: Comparison of Clinical and Thin-Section CT Features During Recovery |pdf=|usr=}}
| |
| − | {{tp|p=32198501|t=ä. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Diagnosis (other modalities)]]''' | | *'''[[Diagnosis (other modalities)]]''' |
| | *'''[[Clinical guidelines and advice]]''' | | *'''[[Clinical guidelines and advice]]''' |
| − | {{tp|p=32283324|t=ä. COVID-19 ? Considerations for the paediatric rheumatologist |pdf=|usr=}}
| |
| − | {{tp|p=32271865|t=ä. Generalizability of COVID-19 Clinical Prediction Models |pdf=|usr=}}
| |
| − | {{tp|p=32338708|t=ä. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32271369|t=ä. Prediction for Progression Risk in Patients with COVID-19 Pneumonia: the CALL Score |pdf=|usr=}}
| |
| − | {{tp|p=32296824|t=ä. A Tool to Early Predict Severe Corona Virus Disease 2019 (COVID-19) : A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 153: |
Zeile 87: |
| | | | |
| | *'''[[Risk and special populations]]''' | | *'''[[Risk and special populations]]''' |
| − | {{tp|p=32371563|t=2020. Asthma increases risk of severity of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32360479|t=ä. 2019 novel coronavirus disease (COVID-19) in hemodialysis patients: a report of two cases |pdf=|usr=}}
| |
| − | {{tp|p=32360811|t=ä. Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts |pdf=|usr=}}
| |
| − | {{tp|p=32334081|t=ä. HEALTH STATUS OF LIVER TRANSPLANTED PATIENTS DURING THE CORONAVIRUS OUTBREAK IN ITALY: A LARGE SINGLE CENTER EXPERIENCE FROM MILAN |pdf=|usr=}}
| |
| − | {{tp|p=32276139|t=2020. COVID-19 in a patient with long-term use of glucocorticoids: A study of a familial cluster |pdf=|usr=}}
| |
| − | {{tp|p=32276140|t=2020. Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients |pdf=|usr=}}
| |
| − | {{tp|p=32249918|t=ä. Maternal and neonatal outcomes of pregnant women with COVID-19 pneumonia: a case-control study |pdf=|usr=}}
| |
| − | {{tp|p=32215613|t=ä. Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System?a Call for Epidemiologic Investigations |pdf=|usr=}}
| |
| − | {{tp|p=32182347|t=ä. Perinatal Transmissionof COVID-19 Associated SARS-CoV-2:Should We Worry?|pdf=|usr=}}
| |
| − | {{tp|p=32161941|t=ä. A case report of neonatal COVID-19 infection in China |pdf=|usr=}}
| |
| − | {{tp|p=32119083|t=ä. A case of 2019 Novel Coronavirus in a pregnant woman with preterm delivery |pdf=|usr=}}
| |
| − | {{tp|p=32271368|t=ä. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission |pdf=|usr=}}
| |
| − | {{tp|p=32270178|t=ä. Early virus clearance and delayed antibody response in a case of COVID-19 with a history of co-infection with HIV-1 and HCV |pdf=|usr=}}
| |
| − | {{tp|p=32353114|t=ä. Throat Wash Testing and COVID-19 Disease: Should We Put Our Money Where Our Mouth Is?|pdf=|usr=}}
| |
| − | {{tp|p=32339215|t=ä. Clinical impact of renin-angiotensin system inhibitors on in-hospital mortality of patients with hypertension hospitalized for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32337584|t=ä. First reported nosocomial outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a pediatric dialysis unit |pdf=|usr=}}
| |
| − | {{tp|p=32297925|t=ä. Sequential analysis of viral load in a neonate and her mother infected with SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32278081|t=ä. Association of COVID-19 infection with pregnancy outcomes in healthcare workers and general women |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Case reports]]''' | | *'''[[Case reports]]''' |
| Zeile 181: |
Zeile 96: |
| | | | |
| | *'''[[Case series]]''' | | *'''[[Case series]]''' |
| − | {{tp|p=32308494|t=2020. Epidemiologic and Clinical Characteristics of 26 Cases of COVID-19 Arising from Patient-to-Patient Transmission in Liaocheng, China |pdf=|usr=}}
| |
| − | {{tp|p=32361723|t=ä. Clinical and laboratory predictors of in-hospital mortality in patients with COVID-19: a cohort study in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32361738|t=ä. Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Hospitalized Patients in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32232322|t=ä. Disparities in Age-Specific Morbidity and Mortality from SARS-CoV-2 in China and the Republic of Korea |pdf=|usr=}}
| |
| − | {{tp|p=32211844|t=ä. Analysis of Epidemiological and Clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan |pdf=|usr=}}
| |
| − | {{tp|p=32179890|t=ä. Risk Factors of Healthcare Workers with Corona Virus Disease 2019: A Retrospective Cohort Study in a Designated Hospital of Wuhan in China |pdf=|usr=}}
| |
| − | {{tp|p=32109279|t=ä. Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study |pdf=|usr=}}
| |
| − | {{tp|p=32112072|t=ä. A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features |pdf=|usr=}}
| |
| − | {{tp|p=32239127|t=ä. Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32337591|t=ä. Early risk factors for the duration of SARS-CoV-2 viral positivity in COVID-19 patients |pdf=|usr=}}
| |
| − | {{tp|p=32176772|t=ä. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32301967|t=ä. SARS-CoV-2 infection (COVID-19) in febrile infants without respiratory distress |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | * | | * |
| | *'''[[Trials]]''' | | *'''[[Trials]]''' |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| − | {{tp|p=32371558|t=2020. Hydroxychloroquine use in the COVID-19 patient |pdf=|usr=}}
| |
| − | {{tp|p=32272008|t=2020. Early preemptive immunomodulators (corticosteroids) for severe pneumonia patients infected with SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32337664|t=ä. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32359035|t=2020. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32272196|t=2020. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology |pdf=|usr=}}
| |
| − | {{tp|p=32247038|t=2020. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32222466|t=2020. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China |pdf=|usr=}}
| |
| − | {{tp|p=32360516|t=ä. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 |pdf=|usr=}}
| |
| − | {{tp|p=32353634|t=2020. COVID-19: Immunology and treatment options |pdf=|usr=}}
| |
| − | {{tp|p=32335290|t=2020. A strategy targeting monocyte-macrophage differentiation to avoid pulmonary complications in SARS-Cov2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32150618|t=ä. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) |pdf=|usr=}}
| |
| − | {{tp|p=32211771|t=ä. Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?|pdf=|usr=}}
| |
| − | {{tp|p=32211764|t=ä. Is Hydroxychloroquine a Possible Postexposure Prophylaxis Drug to Limit the Transmission to Healthcare Workers Exposed to Coronavirus Disease 2019?|pdf=|usr=}}
| |
| − | {{tp|p=32266375|t=ä. Inquiring into Benefits of Independent Activation of Non-Classical Renin-Angiotensin System in the Clinical Prognosis and Reduction of COVID-19 mortality |pdf=|usr=}}
| |
| − | {{tp|p=32255489|t=ä. Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients |pdf=|usr=}}
| |
| − | {{tp|p=32301957|t=ä. Weak Induction of Interferon Expression by SARS-CoV-2 Supports Clinical Trials of Interferon Lambda to Treat Early COVID-19 |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| Zeile 258: |
Zeile 142: |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| − | {{tp|p=32227121|t=ä. The Late Arrival of COVID-19 in Africa - Mitigating Pan-Continental Spread |pdf=|usr=}}
| |
| − | {{tp|p=32201889|t=ä. COVID-19 Transmission Within a Family Cluster by Presymptomatic Carriers in China |pdf=|usr=}}
| |
| − | {{tp|p=32271372|t=ä. Asymptomatic and Presymptomatic Infectors: Hidden Sources of COVID-19 Disease |pdf=|usr=}}
| |
| − | {{tp|p=32255183|t=ä. Lockdown contained the spread of 2019 novel coronavirus disease in Huangshi city, China: Early epidemiological findings |pdf=|usr=}}
| |
| − | {{tp|p=32246149|t=ä. New measures for COVID-19 response: a lesson from the Wenzhou experience |pdf=|usr=}}
| |
| − | {{tp|p=32339245|t=ä. Contact tracing for COVID-19: An opportunity to reduce health disparities and End the HIV/AIDS Epidemic in the US |pdf=|usr=}}
| |
| − | {{tp|p=32339228|t=ä. Interactive web-based graphs of novel coronavirus COVID-19 cases and deaths per population by country |pdf=|usr=}}
| |
| − | {{tp|p=32302377|t=ä. Population movement, city closure in Wuhan and geographical expansion of the 2019-nCoV pneumonia infection in China in January 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32296826|t=ä. The changing patter of COVID-19 in China: A tempo-geographic analysis of the SARS-CoV-2 epidemic |pdf=|usr=}}
| |
| − | {{tp|p=32277759|t=ä. Cluster of coronavirus disease 2019 (Covid-19) in the French Alps, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32234449|t=ä. Molecular characterization of SARS-CoV-2 in the first COVID-19 cluster in France reveals an amino acid deletion in nsp2 (Asp268del) |pdf=|usr=}}
| |
| − | {{tp|p=32301964|t=ä. The characteristics of household transmission of COVID-19 |pdf=|usr=}}
| |
| | | | |
| | *'''[[Failure of politics and public health guidance]]''' | | *'''[[Failure of politics and public health guidance]]''' |
